Enovix Corp: Form 10-Q for the period ended Oct 3, 2021
Filed with the SEC on Nov 15, 2021 and accepted by EDGAR at Nov 15, 2021, 16:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-10-03. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2021-07-01 to 2021-10-03 | $10.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-01-01 to 2021-10-03 | $25.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2021-07-01 to 2021-10-03 | $8.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2021-01-01 to 2021-10-03 | $17.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-07-01 to 2021-10-03 | −$19.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-10-03 | −$44.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-07-01 to 2021-10-03 | −$10.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-10-03 | −$41.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-07-01 to 2021-10-03 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-01-01 to 2021-10-03 | −$0.45 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-07-01 to 2021-10-03 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-01-01 to 2021-10-03 | −$0.38 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-07-01 to 2021-10-03 | 135,052,128 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-01-01 to 2021-10-03 | 109,854,540 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-01-01 to 2021-10-03 | −$34.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-01-01 to 2021-10-03 | $31.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2021-01-01 to 2021-10-03 | $13.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-10-03 | $338.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-10-03 | $346.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-10-03 | $415.4m | us-gaap:Assets |
| Current liabilities | At period end2021-10-03 | $15.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-10-03 | $91.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-10-03 | $323.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-21-004596. Last ingested by Listed: Nov 5, 2026, 12:07 ET. Listed shows no prices and gives no investment advice.